Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanatinostat and Valganciclovir in EBV+ Relapsed/Refractory Lymphomas
NCT05011058Phase 2Terminated
- Sponsor
- Viracta Therapeutics, Inc.
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of nanatinostat in Epstein-Barr virus-positive diffuse large B-cell lymphoma, sponsored by Viracta Therapeutics, Inc.. Started May 2021; status: terminated.
02
Drugs
nanatinostat
03
Conditions
Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on NCT05011058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011058.